Merck (MRK) EBT (2009 - 2026)
Merck (MRK) reported EBT of -$3.5 billion for Q1 2026, down 159.29% year-over-year from $5.9 billion in Q1 2025, and down 202.34% quarter-over-quarter from $3.4 billion in Q4 2025.
Merck (MRK) EBT (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of EBT data on file, last reported at -$3.5 billion in Q1 2026.
- EBT for Q1 2026 came in at -$3.5 billion, down 159.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.7 billion (down 42.17% YoY), and the FY2025 annual result was $21.1 billion, up 5.67% from the prior year.
- EBT declined to -$3.5 billion in Q1 2026 per MRK's latest filing, from $3.4 billion in the prior quarter.
- Over five years, EBT peaked at $6.7 billion in Q3 2025 and troughed at -$5.3 billion in Q2 2023.
- A 5-year average of $3.3 billion and a median of $4.2 billion in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT sank 218.12% in 2023, then jumped 303.81% in 2024.
- A 5-year view of EBT shows it stood at $3.5 billion in 2022, then plunged by 158.24% to -$2.0 billion in 2023, then jumped by 303.81% to $4.2 billion in 2024, then fell by 17.99% to $3.4 billion in 2025, then slumped by 202.34% to -$3.5 billion in 2026.
- Business Quant data shows MRK's EBT at -$3.5 billion in Q1 2026, $3.4 billion in Q4 2025, and $6.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.85 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.99 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.04 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.50 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.08 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.58 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.17 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 3.24 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.50 Bn |
| Dec 31, 2025 | 3.42 Bn |
| Sep 30, 2025 | 6.75 Bn |
| Jun 30, 2025 | 5.00 Bn |
| Mar 31, 2025 | 5.90 Bn |
| Dec 31, 2024 | 4.17 Bn |
| Sep 30, 2024 | 4.09 Bn |
| Jun 30, 2024 | 6.01 Bn |
| Mar 31, 2024 | 5.67 Bn |
| Dec 31, 2023 | -2.05 Bn |
| Sep 30, 2023 | 5.62 Bn |
| Jun 30, 2023 | -5.30 Bn |
| Mar 31, 2023 | 3.65 Bn |
| Dec 31, 2022 | 3.51 Bn |
| Sep 30, 2022 | 3.58 Bn |
| Jun 30, 2022 | 4.49 Bn |
| Mar 31, 2022 | 4.86 Bn |
| Dec 31, 2021 | 3.91 Bn |
| Sep 30, 2021 | 5.27 Bn |
| Jun 30, 2021 | 1.72 Bn |